Integrated Care Management for Older Multimorbid Patients with Atrial Fibrillation: Rationale, Design and Baseline Characteristics for the Atrial Fibrillation Integrated Approach in Frail, Multimorbid and Polymedicated Older People (AFFIRMO) trial

Atrial Fibrillation

Left atrial appendage occlusion versus NOACs in patients with atrial fibrillation: Rationale and design of the CATALYST Trial

Am Heart J

Reddy VY, Hylek E, Camm AJ, Halperin JL, Diener HC, Thaler D, Schmidt B, Hara H, Huisman MV, Price MJ, Lakkireddy D, Gage R, Zhao H, Jensen TP, Quintana M, Windecker S

doi: 10.1016/j.ahj.2026.107367

Heart Failure

Rationale, Design, and Baseline Characteristics of the Virtual Care to Improve Heart Failure Outcomes (VITAL-HF) Trial

Am Heart J

Khan MS, Sauer AJ, Green CL, McDermott J, Khan MS, Chaudhry SP, Haghighat AR, Bennett MK, Martyn T, Shah H, Govil A, Stanis T, Albert NM, DeVore AD

doi: 10.1016/j.ahj.2025.06.001

Cardiac Arrest or Death

Design and rationale of A Multicenter Paramedic randomized trial of noradrenaline versus adrenaline in the initial management of patients with cardiogenic shock - The PANDA trial

Am Heart J

Bloom JE, Ball J, Okyere D, Voskoboinik A, Dawson LP, Nelson AJ, Percival M, Meadley B, Salathiel R, McManamny T, Boggett S, Batchelor R, Hartshorne T, Palmer S, Reid C, Anderson D, Pilcher D, Chew DP, Kaye DM, Nehme Z, Stub D, PANDA Investigators

doi: 10.1016/j.ahj.2026.107378

Atrial Fibrillation

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Heart Rhythm

Boriani G, McIntyre WF, Ramasundarahettige C, Proietti M, Glotzer TV, Diemberger I, Nielsen JC, Essebag V, Granger CB, Sandhu RK, Benezet-Mazuecos J, Mabo P, Coutu B, Wong JA, Gold MR, Lopes RD, Healey JS, ARTESiA Investigators

doi: 10.1016/j.hrthm.2025.07.002

Atrial Fibrillation

Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial

JAMA Cardiol

Metzner A, Willems S, Borof K, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Fabritz L, Gessler N, Goette A, Reissmann B, Schnabel RB, Schotten U, Zapf A, Rillig A, Kirchhof P

doi: 10.1001/jamacardio.2025.2374

Heart, Artery and Coronary Diseases

The Effects of Low-Dose Colchicine on the Progression of Aortic Valve Stenosis: Rationale, Design, and Baseline Characteristics of the Colchicine and Inflammation in Aortic Stenosis (CHIANTI) trial

Am Heart J

Mohammadnia N, Vestjens LTW, Craig NJ, Tijssen JGP, Knol RJJ, Lazarenko SV, Duffels MGJ, Focks JJ, Hemels MEW, Oving I, Schalkx HJ, Eikelboom JW, Cetinyurek-Yavuz A, Aarntzen EHJG, Dey D, Slomka PJ, Nijveldt R, Riksen NP, van Royen N, Honigberg MC, Dweck MR, Cornel JH, Messaoudi SE

doi: 10.1016/j.ahj.2025.07.010

Cardiovascular Risk and DiseasesFurther Publications

Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction

JAMA Cardiol

Ridker PM, Baeres FMM, Hveplund A, Engelmann MMD, Hovingh GK, Lincoff AM, Marx N, Navar AM, Sattar N, Tuttle K, Perkovic V

doi: 10.1001/jamacardio.2025.4491

Atrial Fibrillation

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

J Am Coll Cardiol

Galea R, De Marco F, Aminian A, Meneveau N, Chalkou K, Anselme F, Gräni C, Franzone A, Vranckx P, Fischer U, Valgimigli M, Räber L

doi: 10.1016/j.jacc.2025.03.535

Atrial FibrillationTherapy and Intervention

Rationale and design of the Anticoagulant Therapy after Left Atrial Appendage Closure (ATLAAC) Trial

Am Heart J

Gosvig K, Goller J, Hansson NH, Brandes A, Modrau I, Rasmussen LF, Eskesen K, Jensen AKG, Belley-Côté E, Whitlock R, Riber LPS

doi: 10.1016/j.ahj.2025.04.015

Related content

Left atrial appendage occlusion versus NOACs in patients with atrial fibrillation: Rationale and design of the CATALYST Trial

Rationale, Design, and Baseline Characteristics of the Virtual Care to Improve Heart Failure Outcomes (VITAL-HF) Trial

Design and rationale of A Multicenter Paramedic randomized trial of noradrenaline versus adrenaline in the initial management of patients with cardiogenic shock - The PANDA trial

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial

The Effects of Low-Dose Colchicine on the Progression of Aortic Valve Stenosis: Rationale, Design, and Baseline Characteristics of the Colchicine and Inflammation in Aortic Stenosis (CHIANTI) trial

Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

Rationale and design of the Anticoagulant Therapy after Left Atrial Appendage Closure (ATLAAC) Trial